dc.contributor.author |
Saxton, Peter |
en |
dc.contributor.author |
Giola, M |
en |
dc.contributor.author |
Coughlan, E |
en |
dc.contributor.author |
Rich, J |
en |
dc.contributor.author |
Azariah, S |
en |
dc.contributor.author |
Ludlam, A |
en |
dc.contributor.author |
O'Toole, C |
en |
dc.contributor.author |
Pohl, M |
en |
dc.contributor.author |
Myers, J |
en |
dc.date.accessioned |
2019-03-21T01:40:05Z |
en |
dc.date.issued |
2018-08-31 |
en |
dc.identifier.citation |
New Zealand Medical Journal 131(1481):64-73 31 Aug 2018 |
en |
dc.identifier.issn |
0028-8446 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/46235 |
en |
dc.description.abstract |
HIV pre-exposure prophylaxis (PrEP) is a daily pill that prevents HIV acquisition. In March 2018, New Zealand became one of the first countries in the world to publicly fund PrEP for individuals at high risk. PrEP promises significantly improved HIV control but is unfamiliar to most health practitioners here, compromising its potential. In this article we review the rationale for PrEP and identify barriers to rapid implementation. The latter include: consumer and health practitioner awareness; acceptability; scale-up targets; prescribing and pharmacy bottlenecks; service capacity to manage follow-up; primary care training; monitoring systems for uptake and quality; equity; eligibility; risk compensation and policy. Many of these areas are ripe for research and innovation. By addressing these obstacles we can realise the potential of PrEP and move closer to ending HIV in Aotearoa/New Zealand. |
en |
dc.format.medium |
Electronic |
en |
dc.language |
eng |
en |
dc.publisher |
New Zealand Medical Association |
en |
dc.relation.ispartofseries |
New Zealand Medical Journal |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://www.nzma.org.nz/journal/contribute |
en |
dc.subject |
Humans |
en |
dc.subject |
HIV Infections |
en |
dc.subject |
Amphetamine-Related Disorders |
en |
dc.subject |
Drug Combinations |
en |
dc.subject |
Anti-HIV Agents |
en |
dc.subject |
Treatment Outcome |
en |
dc.subject |
Risk Factors |
en |
dc.subject |
Morals |
en |
dc.subject |
Unsafe Sex |
en |
dc.subject |
Patient Selection |
en |
dc.subject |
Sexual Partners |
en |
dc.subject |
Vulnerable Populations |
en |
dc.subject |
Cost-Benefit Analysis |
en |
dc.subject |
Female |
en |
dc.subject |
Male |
en |
dc.subject |
Healthcare Disparities |
en |
dc.subject |
Pre-Exposure Prophylaxis |
en |
dc.subject |
Tenofovir |
en |
dc.subject |
Emtricitabine |
en |
dc.subject |
Transgender Persons |
en |
dc.subject |
Sexual and Gender Minorities |
en |
dc.title |
Implementing HIV pre-exposure prophylaxis (PrEP): let's not get caught with our pants down |
en |
dc.type |
Journal Article |
en |
pubs.issue |
1481 |
en |
pubs.begin-page |
64 |
en |
pubs.volume |
131 |
en |
dc.rights.holder |
Copyright: NZMA |
en |
pubs.author-url |
https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2018/vol-131-no-1481-31-august-2018/7683 |
en |
pubs.end-page |
73 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
754940 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Population Health |
en |
pubs.org-id |
Social & Community Health |
en |
dc.identifier.eissn |
1175-8716 |
en |
pubs.record-created-at-source-date |
2019-08-15 |
en |
pubs.dimensions-id |
30161114 |
en |